D-Wave Quantum vs. Rigetti Computing: Which Quantum Computing Stock Is a Better Buy in 2026?

Quantum-technology comparison news highlights D-Wave’s 2025 revenue of $24.6M (+178.5% YoY) following its early-2026 acquisition of Quantum Circuits, but it also posted a net loss of $355.1M and free cash flow of -$75.8M. Rigetti reported 2025 revenue of $7.1M (-34.3% YoY) with a net loss of $216.2M and free cash flow of -$77.2M, with heavier reliance on government contracts. The article ultimately leans toward D-Wave as the “better investment right now,” tempered by ongoing high losses, dilution/funding dependence, and technical/execution risks.

Analysis

This is less a technology call than a capital-allocation call. In the next 1-3 months, the market is likely to keep rewarding the name that can point to nearer-term monetization and external validation, but over 6-18 months the binding constraint is not scientific progress — it is dilution, procurement cycles, and whether either company can fund execution without repeatedly resetting the equity story. That makes the sector structurally fragile: every incremental milestone helps the stock, but every financing round or delayed commercialization event can compress multiples quickly.

The key second-order winner is IBM, not the pure plays. Incumbents with enterprise distribution and balance-sheet capacity can absorb quantum R&D as option value, then bundle it into broader cloud/software relationships; that is a much better business model than relying on intermittent government awards or small optimization pilots. The likely loser set is the rest of the speculative quantum basket, because this kind of comparison article tends to reinforce a zero-sum ranking among names with similar narratives but very different cash burn profiles.

Contrarian view: the consensus is overestimating how much near-term stock performance will track technical architecture. For these names, the real driver is funding access and narrative durability, so the “best technology” may underperform the “best financed” company for years. The trade is therefore not to chase outright beta; it is to own relative quality and avoid names where one failed contract cycle or equity raise can reverse the thesis in days, not months.

Key Decisions for Investors

• Relative-value trade: long QBTS / short RGTI for 1-3 months. QBTS has the better funding narrative and more credible near-term commercialization path; target 15-25% spread capture, with a hard stop if QBTS integration or government support disappoints.
• Prefer IBM over any pure-play quantum exposure on a 6-18 month horizon. Long IBM / short an equal-dollar basket of QBTS and RGTI is the cleaner expression of 'monetization beats narrative'; thesis breaks if either startup shows sustained revenue acceleration and reduced cash burn for two consecutive quarters.
• Avoid naked long exposure in RGTI at current levels. If already long, sell calls or trim into strength ahead of any contract-update or financing event; the main downside catalyst is dilution or a guide-down on customer concentration.
• Treat QBTS as a trading vehicle, not a core position. Use pullbacks after hype-driven rallies rather than chasing breakouts; upside remains optionality-driven, but the risk/reward deteriorates quickly if the market starts pricing a slower adoption curve.